Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
conversion in patients with MAC lung disease who were largely treatment-naïve, with a safety profile consistent with prior experience. Insmed now plans sNDA and PMDA submissions in the second half of 2026, aiming to expand ARIKAYCE's label beyond its current refractory indication and potentially reshape first-line care for MAC lung infection. We'll now examine how ARIKAYCE's Phase 3b ENCORE success and potential label expansion could reshape Insmed's previously outlined investment narrative. AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. Insmed Investment Narrative Recap To own Insmed, you need to believe it can convert its respiratory portfolio into durable, high-margin revenue while managing ongoing losses and funding needs. The ENCORE Phase 3b success reinforces ARIKAYCE as a core asset and strengthens the case
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.MarketBeat
- Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.MarketBeat
- Columbia Select Large Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 4/1/26 - Form ARS
- INSM's page on the SEC website